Cargando…

PB2527: COMPARING REAL-LIFE VERSUS PREDICTED PARAMETERS WITH OPTIA SPECTRA IN RED BLOOD CELL EXCHANGE IN SICKLE-CELL DISEASE PATIENTS

Detalles Bibliográficos
Autores principales:	Rumschisky, Pablo Palomo, Núñez, Maria Tenorio, Kennedy, Kyra Velázquez, Martín, Ana Jiménez, Carbonero, Ana Vallés, Rodríguez, Alberto González, Noguerales, Blanca De Felipe, Bolea, Lucia, Jimenez, Francisco Lopez, Moreno-Jiménez, Gemma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429712/ http://dx.doi.org/10.1097/01.HS9.0000976808.83073.22

Ejemplares similares

PB2340: INFLUENCE OF INITIAL CLINICAL FEATURES IN THERAPEUTIC DECISIONS AND DIAGNOSTIC PROCESS OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA. A REAL WORLD EXPERIENCE
por: Bolea, L., et al.
Publicado: (2022)

Therapeutic Plasma Exchange Using the Spectra Optia Cell Separator Compared With the COBE Spectra
por: Kim, Do-kyun, et al.
Publicado: (2015)

Spectra Optia(®) for Automated Red Blood Cell Exchange in Patients with Sickle Cell Disease: A NICE Medical Technology Guidance
por: Willits, Iain, et al.
Publicado: (2017)

Effective sickle hemoglobin reduction by automated red cell exchange using Spectra Optia in three Emirati patients with sickle cell disease before allogeneic hematopoietic stem cell transplantation
por: Choi, Seung Jun, et al.
Publicado: (2018)

The safety and performance of the Spectra Optia apheresis system platelet depletion protocol in patients with elevated platelet counts
por: Lopert, Pamela, et al.
Publicado: (2022)

PB2510: CHARACTERISATION OF SICKLE CELL DISEASE PATIENTS: A PORTUGUESE REAL-WORLD STUDY (ASCEND)
por: Deveza, Maria Manuel, et al.
Publicado: (2023)

PB2528: THE IMPACT OF ZINC SUPPLEMENTATION ON HYPERBILIRUBINEMIA IN SICKLE CELL DISEASE
por: Al Farttoosi, Mohammed
Publicado: (2023)

PB2517: OSTEOMYELITIS IN CHILDREN WITH SICKLE CELL DISEASE: IS MRI PATHOGNOMONIC?
por: Al Lawati, Murtadha, et al.
Publicado: (2023)

Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC
por: Kim-Wanner, Soo-Zin, et al.
Publicado: (2017)

PB2215: GLOBAL EPIDEMIOLOGY OF SICKLE CELL DISEASE: A SYSTEMATIC LITERATURE REVIEW
por: Colombatti, R., et al.
Publicado: (2022)

PB2513: A RE-AUDIT OF PAIN MANAGEMENT IN SICKLE CELL PAIN CRISES
por: Zhou, Yuhui, et al.
Publicado: (2023)

PB2507: EFFECTS OF TSH ON HEMOGLOBIN S POLYMERIZATION, DEFORMABILITY AND ADHESION ON SICKLE CELL ERYTHROCYTES
por: Reis, Evelyn Mendonça, et al.
Publicado: (2023)

PB2217: SICKLE CELL DISEASE IS A RISK FACTOR FOR THE PROGRESSION AND PROGNOSIS OF COVID-19
por: Goyal, V., et al.
Publicado: (2022)

PB2504: USE OF CONSUMER WEARABLES TO MONITOR AND PREDICT PAIN IN PATIENTS WITH SICKLE CELL DISEASE
por: Vuong, Caroline, et al.
Publicado: (2023)

PB1940: REAL-LIFE EXPERIENCE OF THE IMMUNE RECONSTITUTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND SMALL LYMPHOCYTIC LYMPHOMA TREATED WITH IBRUTINIB.
por: Pérez, Belén Olivares, et al.
Publicado: (2023)

PB2224: IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM THE REAL WORLD ASSESSMENT SURVEY FOR SICKLE CELL DISEASE IN SAUDI (ROARS)
por: Ezzat, H., et al.
Publicado: (2022)

PB2223: COST OF ILLNESS, EPIDEMIOLOGY AND HEALTHCARE RESOURCE UTILIZATION FOR SICKLE CELL DISEASE IN THE GULF “CESGU”
por: Soliman, D., et al.
Publicado: (2022)

PB2225: ENVIRONMENTAL MODIFIERS OF SEVERITY IN CHILDREN WITH SICKLE CELL DISEASE: A FEASIBILITY PILOT STUDY
por: Strouse, J., et al.
Publicado: (2022)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

PB2505: THERAPEUTIC PHLEBOTOMY INSTANTLY AFFECTS BLOOD PARAMETERS AND VISCOCITY IN SICKLE CELL DISEASE PATIENTS
por: Jebali, Amna, et al.
Publicado: (2023)

PB2514: IMMUNOGENICITY OF ANTI-SARS-COV-2 VACCINES IN PATIENTS WITH SEVERE SICKLE CELL DISEASE
por: Meunier, Benoit, et al.
Publicado: (2023)

PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS
por: Abboud, Miguel, et al.
Publicado: (2023)

PB2508: COMPARING DEFINITIONS OF EPISODES OF VASO-OCCLUSION AS ENDPOINTS IN CLINICAL STUDIES OF SICKLE CELL DISEASE
por: Locatelli, Franco, et al.
Publicado: (2023)

PB2216: VACUOLES APPEAR IN RED BLOOD CELLS TRANSFUSED TO PATIENTS WITH SICKLE CELL DISEASE-RELATED HYPOSPLENISM
por: Dumas, L., et al.
Publicado: (2022)

PB2226: THE ROLE OF COMPLEMENT IN THE IMMUNE RESPONSE OF SICKLE CELL DISEASE PATIENTS AFER COVID-19 VACCINATION
por: Varelas, C., et al.
Publicado: (2022)

PB2221: A SYSTEMATIC LITERATURE REVIEW DESCRIBING PROTECTIVE EFFECTS OF HBF IN SICKLE CELL DISEASE OUTCOMES
por: Mitelman, O., et al.
Publicado: (2022)

PB2526: UMBILICAL CORD BLOOD SCREENING FOR SICKLE CELL DISEASE: A PILOT STUDY IN THE NORTH OF TUNISIA
por: Ouragini, Houyem, et al.
Publicado: (2023)

PB2511: CLINICAL COMPLICATIONS AMONG PATIENTS WITH SICKLE CELL DISEASE WITH RECURRENT VASO-OCCLUSIVE CRISES IN GERMANY
por: Udeze, Chuka, et al.
Publicado: (2023)

PB2295: EVANS SYNDROME AND PHENOTYPIC HETEROGENEITY OF SASH3 GERMLINE LOSS-OF-FUNCTION MUTATIONS BEYOND X-LINKED IMMUNODEFICIENCY
por: Berner, J., et al.
Publicado: (2022)

PB2222: THE PROTECTIVE EFFECT OF THE SPLEEN IN SICKLE CELL PATIENTS. A COMPARATIVE STUDY BETWEEN PATIENTS WITH ASPLENIA AND HYPERSPLENISM.
por: Peretz, S., et al.
Publicado: (2022)

PB2522: LIPID PROFILE AND CARDIAC FUNCTIONS IN EGYPTIAN SICKLE CELL DISEASE PATIENTS: A SINGLE CENTER STUDY
por: El Ghamrawy, Mona, et al.
Publicado: (2023)

A Report on 2527 Cases of Primary Suture
Publicado: (1918)

PB2091: INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA
por: Zamanillo, I., et al.
Publicado: (2022)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
por: José Jiménez Nájar, Francisco, et al.
Publicado: (2023)

PB2227: HEALTH-RELATED QUALITY OF LIFE OVER TIME IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE ADMITTED FOR VASO-OCCLUSIVE CRISIS.
por: Vuong, C., et al.
Publicado: (2022)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

PB2026: CONSENSUS STATEMENT: IMPORTANCE OF TIMELY ACCESS TO MULTIPLE MYELOMA DIAGNOSIS AND TREATMENT IN CENTRAL AMERICA AND THE CARIBBEAN
por: Pimentel, M., et al.
Publicado: (2022)

PB2335: BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICAID PATIENTS WITH SICKLE CELL DISEASE (SCD): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE
por: Aggarwal, S., et al.
Publicado: (2022)

PB2219: A REAL-WORLD EXPERIENCE WITH HEALTHCARE RESOURCE UTILIZATION PATTERNS AND RELATED COSTS IN PATIENTS WITH SICKLE CELL DISEASE IN NORTH LEBANON
por: Inati, A., et al.
Publicado: (2022)

PB2519: THE EFFECT OF PREVENTIVE HEALTH PROGRAM ON KNOWLEDGE AND SCREENING OF SICKLE CELL DISEASE AMONG HIGH SCHOOL AGED GROUP – THE SAUDI ARABIA EXPERIENCE
por: Ezzat, Hatoon
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hhqpd3sjr6lgsjpcl1q7ndo7hv